Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05558566 · ClinicalTrials.gov registry record · NA

Neurofeedback From the Supplementary Motor Area for Tourette Syndrome

A NA study of Tourette Syndrome in Adolescence, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
64
Enrollment target
1
Study location

NCT05558566 is a NA study of Tourette Syndrome in Adolescence that is actively recruiting participants, run by Yale University. The registered enrollment target is 64 participants, above the 35-participant average among 5 other Tourette Syndrome in Adolescence trials with a reported enrollment target (83% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05558566, a NA study of Tourette Syndrome in Adolescence, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).

Interventions

  • OTHER Neurofeedback from the SMA
  • OTHER Neurofeedback from control region

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2022-11-01
Est. Completion 2027-01-20
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT05558566

The ClinicalTrials.gov registry entry for NCT05558566 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 5 other Tourette Syndrome in Adolescence trials with a reported enrollment target (83% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tourette Syndrome in Adolescence appearing as the primary indexed condition, and to 2 interventions - of which Neurofeedback from the SMA is the first listed.

NCT05558566 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05558566 about?

NCT05558566 is a clinical study titled "Neurofeedback From the Supplementary Motor Area for Tourette Syndrome". This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-ti...

What is the current status of trial NCT05558566?

This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2022-11-01. Estimated completion is 2027-01-20.

What conditions does trial NCT05558566 study?

This clinical trial studies the following conditions: Tourette Syndrome in Adolescence.

What interventions are being tested in trial NCT05558566?

The interventions under investigation include: Neurofeedback from the SMA (OTHER), Neurofeedback from control region (OTHER).

Who is sponsoring clinical trial NCT05558566?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05558566 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tourette Syndrome in Adolescence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.